Home > Products > CD3 & PSMA
> Recombinant Anti-CD3 x Anti-PSMA Bispecific Antibody (VHH-IgG)
Recombinant Anti-CD3 x Anti-PSMA Bispecific Antibody (VHH-IgG) (CAT#: BSSG-387)
Recombinant Anti-CD3 x Anti-PSMA Bispecific Antibody (VHH-IgG) is formed by an IgG and two VHH fragments. The VHHs from an anti-PSMA antibody variable domain are respectively connected to the N terminus of the anti-CD3 IgG heavy chains or light chains to form VHH-(H)IgG or VHH-(L)IgG. It is a type of appended IgGs and has 2+2 antigen-binding valency. This BsAb can retarget T cells to tumor cells. It is designed for the research of Prostate cancer therapy.
CD3 (Cluster of differentiation 3), originally known as T3, is one of the first groups of human T lymphocyte surface antigens recognized by monoclonal antibodies. It has been reported that antibodies against CD3 could either stimulate T cells to divide or inhibit the progress of effector functions according to the conditions used. It plays an important role in T cell and the CD3 T-cell co-receptor helps to activate the cytotoxic T-Cell and T helper cells. The CD3 molecule is composed of a protein complex and consists of four distinct chains. The complex of mammals contains a CD3γ chain, a CD3δ chain, and two CD3ε chains. All these chains associate with T-cell receptor and the ζ-chain to generate an activation signal in T lymphocytes.
There are currently no customer reviews or questions for Recombinant Anti-CD3 x Anti-PSMA Bispecific Antibody (VHH-IgG) (BSSG-387). Click the button below to contact us or submit your feedback about this product.